Kevin J. Hamblett

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

Kevin J. Hamblett, Peter D. Senter, Dana F. Chace et al. · Clinical Cancer Research · 2004 · 1.2K citations

Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides

Michael Sun, Kevin S. Beam, Charles G. Cerveny et al. · Bioconjugate Chemistry · 2005 · 359 citations · Full text

Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment

Charlotte F. McDonagh, Eileen Turcott, Lori Westendorf et al. · Protein Engineering Design and Selection · 2006 · 236 citations · Full text

Medicinal Chemistry, Parental Antibody-drug Conjugates, Medicine +15

SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm

Kevin J. Hamblett, Allison P. Jacob, Jesse L. Gurgel et al. · Cancer Research · 2015 · 128 citations

Protein Secretion, Drug Targeting, Natural Sciences +15

AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma

Kevin J. Hamblett, Carl J. Kozlosky, Sophia Siu et al. · Molecular Cancer Therapeutics · 2015 · 99 citations